vs
CASTLE BIOSCIENCES INC（CSTL）与RadNet, Inc.（RDNT）财务数据对比。点击上方公司名可切换其他公司
RadNet, Inc.的季度营收约是CASTLE BIOSCIENCES INC的6.3倍（$547.7M vs $87.0M）。RadNet, Inc.同比增速更快（14.8% vs 0.8%）。过去两年RadNet, Inc.的营收复合增速更高（12.6% vs 9.2%）
Castle Biosciences是一家处于商业阶段的诊断企业，专注于开发和商业化针对黑色素瘤等皮肤癌及罕见病的专利临床诊断检测产品，主要服务美国医疗市场，聚焦未被满足的精准诊断需求领域，辅助临床医生制定治疗决策。
RadNet是美国领先的放射医疗服务企业，总部位于加利福尼亚州洛杉矶，是美国规模最大的独立固定地址诊断影像中心运营商，按网点数量及年度影像业务收入计均居行业首位。截至2025年，该公司在全美8个州持有或运营超400家影像中心，提供门诊诊断影像服务。
CSTL vs RDNT — 直观对比
营收规模更大
RDNT
是对方的6.3倍
$87.0M
营收增速更快
RDNT
高出14.0%
0.8%
两年增速更快
RDNT
近两年复合增速
9.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $87.0M | $547.7M |
| 净利润 | — | $-597.0K |
| 毛利率 | 79.0% | — |
| 营业利润率 | -4.4% | 5.1% |
| 净利率 | — | -0.1% |
| 营收同比 | 0.8% | 14.8% |
| 净利润同比 | — | -111.2% |
| 每股收益（稀释后） | $-0.06 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSTLRDNT
| Q4 25 | $87.0M | $547.7M | ||
| Q3 25 | $83.0M | $522.9M | ||
| Q2 25 | $86.2M | $498.2M | ||
| Q1 25 | $88.0M | $471.4M | ||
| Q4 24 | $86.3M | $477.1M | ||
| Q3 24 | $85.8M | $461.1M | ||
| Q2 24 | $87.0M | $459.7M | ||
| Q1 24 | $73.0M | $431.7M |
净利润CSTLRDNT
| Q4 25 | — | $-597.0K | ||
| Q3 25 | $-501.0K | $5.4M | ||
| Q2 25 | $4.5M | $14.5M | ||
| Q1 25 | $-25.8M | $-37.9M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | $2.3M | $3.2M | ||
| Q2 24 | $8.9M | $-3.0M | ||
| Q1 24 | $-2.5M | $-2.8M |
毛利率CSTLRDNT
| Q4 25 | 79.0% | — | ||
| Q3 25 | 77.5% | — | ||
| Q2 25 | 79.5% | — | ||
| Q1 25 | 81.4% | — | ||
| Q4 24 | 81.3% | — | ||
| Q3 24 | 81.8% | — | ||
| Q2 24 | 83.3% | — | ||
| Q1 24 | 81.0% | — |
营业利润率CSTLRDNT
| Q4 25 | -4.4% | 5.1% | ||
| Q3 25 | -8.2% | 5.2% | ||
| Q2 25 | -4.9% | 6.2% | ||
| Q1 25 | -31.7% | -5.1% | ||
| Q4 24 | 4.7% | 5.1% | ||
| Q3 24 | 5.9% | 7.4% | ||
| Q2 24 | 5.8% | 7.6% | ||
| Q1 24 | -7.5% | 2.6% |
净利率CSTLRDNT
| Q4 25 | — | -0.1% | ||
| Q3 25 | -0.6% | 1.0% | ||
| Q2 25 | 5.2% | 2.9% | ||
| Q1 25 | -29.4% | -8.0% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 2.6% | 0.7% | ||
| Q2 24 | 10.3% | -0.6% | ||
| Q1 24 | -3.5% | -0.6% |
每股收益（稀释后）CSTLRDNT
| Q4 25 | $-0.06 | $0.00 | ||
| Q3 25 | $-0.02 | $0.07 | ||
| Q2 25 | $0.15 | $0.19 | ||
| Q1 25 | $-0.90 | $-0.51 | ||
| Q4 24 | $0.32 | $0.08 | ||
| Q3 24 | $0.08 | $0.04 | ||
| Q2 24 | $0.31 | $-0.04 | ||
| Q1 24 | $-0.09 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $299.5M | $767.2M |
| 总债务越低越好 | $10.1M | $1.1B |
| 股东权益账面价值 | $470.9M | $1.1B |
| 总资产 | $578.6M | $3.8B |
| 负债/权益比越低杠杆越低 | 0.02× | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资CSTLRDNT
| Q4 25 | $299.5M | $767.2M | ||
| Q3 25 | $287.5M | $804.7M | ||
| Q2 25 | $275.9M | $833.2M | ||
| Q1 25 | $275.2M | $717.3M | ||
| Q4 24 | $293.1M | $740.0M | ||
| Q3 24 | $95.0M | $748.9M | ||
| Q2 24 | $85.6M | $741.7M | ||
| Q1 24 | $82.9M | $527.0M |
总债务CSTLRDNT
| Q4 25 | $10.1M | $1.1B | ||
| Q3 25 | $10.0M | $1.1B | ||
| Q2 25 | $10.0M | $1.1B | ||
| Q1 25 | $10.0M | $1.0B | ||
| Q4 24 | $10.0M | $1.0B | ||
| Q3 24 | $10.0M | $1.0B | ||
| Q2 24 | $10.0M | $1.0B | ||
| Q1 24 | $10.0M | $834.6M |
股东权益CSTLRDNT
| Q4 25 | $470.9M | $1.1B | ||
| Q3 25 | $467.0M | $1.1B | ||
| Q2 25 | $455.4M | $932.3M | ||
| Q1 25 | $440.3M | $898.1M | ||
| Q4 24 | $455.8M | $902.3M | ||
| Q3 24 | $441.1M | $895.3M | ||
| Q2 24 | $423.9M | $881.0M | ||
| Q1 24 | $402.5M | $873.0M |
总资产CSTLRDNT
| Q4 25 | $578.6M | $3.8B | ||
| Q3 25 | $562.8M | $3.7B | ||
| Q2 25 | $544.7M | $3.5B | ||
| Q1 25 | $501.7M | $3.3B | ||
| Q4 24 | $531.2M | $3.3B | ||
| Q3 24 | $514.6M | $3.3B | ||
| Q2 24 | $487.3M | $3.2B | ||
| Q1 24 | $458.5M | $3.0B |
负债/权益比CSTLRDNT
| Q4 25 | 0.02× | 1.00× | ||
| Q3 25 | 0.02× | 1.04× | ||
| Q2 25 | 0.02× | 1.18× | ||
| Q1 25 | 0.02× | 1.12× | ||
| Q4 24 | 0.02× | 1.13× | ||
| Q3 24 | 0.02× | 1.14× | ||
| Q2 24 | 0.02× | 1.17× | ||
| Q1 24 | 0.02× | 0.96× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $26.9M | $84.2M |
| 自由现金流经营现金流 - 资本支出 | $19.7M | — |
| 自由现金流率自由现金流/营收 | 22.7% | — |
| 资本支出强度资本支出/营收 | 8.3% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $28.3M | — |
8季度趋势，按日历期对齐
经营现金流CSTLRDNT
| Q4 25 | $26.9M | $84.2M | ||
| Q3 25 | $22.6M | $52.8M | ||
| Q2 25 | $20.8M | $120.3M | ||
| Q1 25 | $-6.0M | $41.5M | ||
| Q4 24 | $24.4M | $42.5M | ||
| Q3 24 | $23.3M | $57.4M | ||
| Q2 24 | $24.0M | $116.0M | ||
| Q1 24 | $-6.8M | $17.1M |
自由现金流CSTLRDNT
| Q4 25 | $19.7M | — | ||
| Q3 25 | $7.8M | — | ||
| Q2 25 | $11.6M | — | ||
| Q1 25 | $-10.8M | — | ||
| Q4 24 | $16.8M | — | ||
| Q3 24 | $17.0M | — | ||
| Q2 24 | $18.8M | — | ||
| Q1 24 | $-16.0M | — |
自由现金流率CSTLRDNT
| Q4 25 | 22.7% | — | ||
| Q3 25 | 9.4% | — | ||
| Q2 25 | 13.4% | — | ||
| Q1 25 | -12.2% | — | ||
| Q4 24 | 19.5% | — | ||
| Q3 24 | 19.8% | — | ||
| Q2 24 | 21.6% | — | ||
| Q1 24 | -21.9% | — |
资本支出强度CSTLRDNT
| Q4 25 | 8.3% | — | ||
| Q3 25 | 17.9% | — | ||
| Q2 25 | 10.7% | — | ||
| Q1 25 | 5.4% | — | ||
| Q4 24 | 8.8% | — | ||
| Q3 24 | 7.4% | — | ||
| Q2 24 | 6.0% | — | ||
| Q1 24 | 12.5% | — |
现金转化率CSTLRDNT
| Q4 25 | — | — | ||
| Q3 25 | — | 9.75× | ||
| Q2 25 | 4.60× | 8.33× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 7.96× | ||
| Q3 24 | 10.29× | 17.89× | ||
| Q2 24 | 2.69× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSTL
| Dermatologic | $48.6M | 56% |
| Non Dermatologic | $38.4M | 44% |
RDNT
| Commercial Insurance1 | $301.0M | 55% |
| Medicare1 | $129.2M | 24% |
| Capitation Arrangements | $31.9M | 6% |
| Health Care Other | $20.4M | 4% |
| Digital Health | $16.4M | 3% |
| Other | $15.2M | 3% |
| Medicaid1 | $14.0M | 3% |
| Workers Compensation Personal Injury1 | $12.3M | 2% |
| Health Care Management Service | $7.5M | 1% |
